(ethoxymethoxy)benzene | 826-21-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: (ethoxymethoxy)benzene
• 英文别名: Ethoxymethoxybenzene
• CAS: 826-21-1
• 化学式: C₉H₁₂O₂
• 分子量: 152.193
• InChiKey: CUSOSRUJNZIYSE-UHFFFAOYSA-N

物化性质

• 沸点：
  76.5-76.7 °C(Press: 8 Torr)
• 密度：
  1.0306 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (ethoxymethoxy)benzene 、 六羰基铬 以 四氢呋喃 为溶剂， 反应 48.0h， 以81%的产率得到η6-(ethoxymethoxybenzene)tricarbonylchromium(0)
  参考文献：
  名称：

  调节简单芳烃在 C-H 活化中的反应性和位点选择性：通过芳烃-金属 π 络合对苯甲醚进行邻位芳基化

  摘要：

  目前在芳烃 C-H 活化中实现位点选择性的方法涉及使用导向基团或高度缺电子的芳烃。相比之下，简单的芳烃，例如苯甲醚，其特点是反应性和选择性差。我们报告说，与 Cr(CO)3 单元的 π 络合增强了苯甲醚的反应活性，从而提供了前所未有的邻位选择性芳基化。这种温和的方法可用于含有苯甲醚基序的生物活性化合物的后期功能化，从而可以通过很少的合成步骤构建新型有机支架。

  DOI：

  10.1021/ja510260j
• 作为产物：
  描述：

  二乙氧基甲烷 、 苯酚 在 montmorillonite 作用下， 以72%的产率得到(ethoxymethoxy)benzene
  参考文献：
  名称：

  Die Einführung derO-Ethoxymethyl-Gruppe zum Schutz der Hydroxy-Gruppe in Alkoholen and Phenolen

  摘要：

  DOI：

  10.1055/s-1981-29598

文献信息

• THERAPEUTIC AGENT FOR DIABETES
  申请人：Japan Tobacco Inc.

  公开号：EP0885869A1

  公开（公告）日：1998-12-23

  A therapeutic agent for diabetes, which comprises a compound of the formula [I] wherein Xis a group of the formula wherein R4 and R5 are the same or different and each is a hydrogen atom, an optionally substituted alkyl having 1 to 5 carbon atoms and the like, and R6 is a hydrogen atom or an amino-protecting group; R1 is an optionally substituted alkyl having 1 to 5 carbon atoms, an optionally substituted alkenyl having 2 to 6 carbon atoms and the like, R2 is a hydrogen atom, an optionally substituted alkyl having 1 to 5 carbon atoms and the like, R2' is a hydrogen atom, and R3 is an optionally substituted alkyl having 1 to 5 carbon atoms and the like, a prodrug thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof and a solvate thereof. The compound of the present invention shows superior blood sugar decreasing action on the state of hyperglycemia, but does not affect the blood sugar when it is in the normal range or in the hypoglycemic state, which means that it is free of serious side effects such as hypoglycemia. Therefore, the compound of the present invention is useful as a therapeutic drug for diabetes and also useful as a preventive of the chronic complications of diabetes.

  用于治疗糖尿病的疗法剂，包括公式[I]的化合物 其中 X是公式的组 其中R4和R5相同或不同，每个都是氢原子，可选地取代的具有1至5个碳原子的烷基等等，R6是氢原子或氨基保护基团；R1是具有1至5个碳原子的可选取代烷基，具有2至6个碳原子的可选取代烯基等等，R2是氢原子，具有1至5个碳原子的可选取代烷基等等，R2'是氢原子，R3是具有1至5个碳原子的可选取代烷基等等，其前药，药用可接受盐，水合物和溶剂化物。 本发明的化合物在血糖升高状态下表现出优越的降血糖作用，但在正常范围或低血糖状态下不影响血糖，这意味着它没有低血糖等严重副作用。因此，本发明的化合物作为治疗糖尿病的药物很有用，也用作预防糖尿病慢性并发症。
• BITTER TASTE MODIFIERS INCLUDING SUBSTITUTED 1-BENZYL-3-(1-(ISOXAZOL-4-YLMETHYL)-1H-PYRAZOL-4-YL)IMIDAZOLIDINE-2,4-DIONES AND COMPOSITIONS THEREOF
  申请人：SENOMYX, INC.

  公开号：US20160376263A1

  公开（公告）日：2016-12-29

  The present invention includes compounds and compositions known to modify the perception of bitter taste, and combinations of said compositions and compounds with additional compositions, compounds, and products. Exemplary compositions comprise one or more of the following: cooling agents; inactive drug ingredients; active pharmaceutical ingredients; food additives or foodstuffs; flavorants, or flavor enhancers; food or beverage products; bitter compounds; sweeteners; bitterants; sour flavorants; salty flavorants; umami flavorants; plant or animal products; compounds known to be used in pet care products; compounds known to be used in personal care products; compounds known to be used in home products; pharmaceutical preparations; topical preparations; cannabis-derived or cannabis-related products; compounds known to be used in oral care products; beverages; scents, perfumes, or odorants; compounds known to be used in consumer products; silicone compounds; abrasives; surfactants; warming agents; smoking articles; fats, oils, or emulsions; and/or probiotic bacteria or supplements.

  本发明涵盖已知用于改变苦味感知的化合物和组合物，以及所述组合物和化合物与额外的组合物、化合物和产品的组合。示例组合物包括以下一种或多种：冷却剂；无活性药物成分；活性药用成分；食品添加剂或食品；调味剂或调味增强剂；食品或饮料产品；苦味化合物；甜味剂；苦味剂；酸味调味剂；咸味调味剂；鲜味调味剂；植物或动物产品；已知用于宠物护理产品中的化合物；已知用于个人护理产品中的化合物；已知用于家用产品中的化合物；制药制剂；局部制剂；大麻衍生或与大麻相关的产品；已知用于口腔护理产品中的化合物；饮料；香味、香水或除臭剂；已知用于消费品中的化合物；硅化合物；磨料；表面活性剂；发热剂；吸烟物品；脂肪、油脂或乳化剂；和/或益生菌或补充剂。
• Catalytic Properties of Chromium Complexes Based on 1,2-Bis(diphenylphosphino)benzene in the Ethylene Oligomerization Reaction
  作者：D. N. Cheredilin、A. M. Sheloumov、A. A. Senin、G. A. Kozlova、V. V. Afanas’ev、N. B. Bespalova

  DOI：10.1134/s0965544119130036

  日期：2019.12

  catalyst systems of a number of diphosphine ligands and chromium complexes based on 1,2-bis(diphenylphosphino)benzene in the ethylene oligomerization reaction has been studied. Structural modifications of diphosphine ligands have been performed to create selective catalyst systems for ethylene oligomerization. It has been shown that the introduction of ortho-functional groups into one of the phenyl substituents

  摘要研究了许多基于1,2-双（二苯基膦基）苯的二膦配体和铬配合物的催化剂体系在乙烯低聚反应中的活性。已经进行了二膦配体的结构修饰以产生用于乙烯低聚的选择性催化剂体系。已经表明，在二膦配体的磷原子上将邻官能团引入到苯基取代基中的一个苯基取代基上，使得可以进行乙烯低聚为1-己烯的方法，其选择性为90wt％以上。配合物之一（铬配合物15）具有功能化的二膦配体）已通过X射线结构分析进行了表征。已经研究了活化剂的量及其类型的变化对催化剂体系活性的影响。已经表明，用三甲基铝代替某些有机铝活化剂甲基铝氧烷不会降低基于二膦铬配合物的催化剂体系的生产率和选择性。
• COMPOUNDS USEFUL AS MODULATORS OF TRPM8
  申请人：Senomyx, Inc.

  公开号：US20170096418A1

  公开（公告）日：2017-04-06

  The present disclosure relates to compounds which are useful as cooling sensation compounds.

  本公开涉及作为冷感化合物有用的化合物。
• [EN] X-RAY AND GAMMA-PHOTON ACTIVABLE ORGANIC COMPOUNDS, THEIR PREPARATION AND THEIR USES<br/>[FR] COMPOSÉS ORGANIQUES ACTIVABLES PAR LES RAYONS X ET LES PHOTONS GAMMA, LEUR PRÉPARATION ET LEURS UTILISATIONS
  申请人：CENTRE NAT RECH SCIENT

  公开号：WO2011158189A1

  公开（公告）日：2011-12-22

  The present invention relates to a X-ray and gamma-photon activable compound responding to the following formula (I). The present invention also relates to methods of synthesizing a compound according to the invention, and to an aqueous or physiological solution comprising at least one compound of the invention. The present invention also concerns a method of liberating a biologically active compound, said method involving the step of irradiating at least one compound, or at least one aqueous or physiological solution according to the invention. Finally, the present invention relates to a pharmaceutical composition comprising at least one compound, or at least one aqueous or physiological solution according to the invention.

  本发明涉及一种与以下式（I）相应的X射线和γ光子可激活化合物。本发明还涉及根据本发明合成化合物的方法，以及包含至少一种本发明合成物的水溶液或生理溶液。本发明还涉及一种释放生物活性化合物的方法，该方法涉及辐照至少一种化合物或至少一种根据本发明的水溶液或生理溶液的步骤。最后，本发明涉及一种包含至少一种本发明合成物或至少一种根据本发明的水溶液或生理溶液的药物组合物。